1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases. Supports research and/or preclinical development of highly efficacious vaccines against malaria by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the funder's official program page to help you evaluate fit faster.
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) - Federal Grant Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) The summary for the Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants. com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact .
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed): The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines.
The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) National Institutes of Health (HHS-NIH11) Funding Opportunity Number: Current Application Deadline: Original Application Deadline: Maximum Federal Grant Award: Minimum Federal Grant Award: Expected Number of Awards: Cost Sharing or Matching: Applicants Eligible for this Grant State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility Refer to Section III. Eligibility Information in the NOFO for additional information on eligibilityForeign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations.
See NIH Grants Policy Statement 16. 8 Collaborative International Research Awards. Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding.
This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Grant Announcement Contact Malaria and Other Mosquito Borne Diseases Similar Government Grants • Immune Tolerance Network (UM1 Clinical Trial Required) • Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) • Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) • Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) • NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) • Center for HIV/AIDS Vaccine Immunology (CHAVI) • Genomics of Transplantation Cooperative Research Program • Asthma and Allergic Diseases Cooperative Research Centers More Grants from the National Institutes of Health • Gabriella Miller Kids First Training and Outreach Core (U24 Clinical Trial Not Allowed) • Genomic Data Generation Center for the Gabriella Miller Kids First Pediatric Research Prog...
• Single Source: Continued Development of the Gabriella Miller Kids First Pediatric Data Res... • NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices ... • Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinic...
Federal Grants by Category Grants for Single Mothers Small Business Grants for Women Federal Grants for College Federal Tuition Assistance
According to the current listing, eligibility includes: Public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations including small businesses, state governments…. Confirm the full requirements in the official notice before applying.
The current listing shows $4,000,000 total for 5-7 awards; R61 phase up to $400,000 direct costs annually; R33 phase up to $750,000 direct costs annually. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) are due February 11, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) is funded by National Institute of Allergy and Infectious Diseases. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
RFA-AI-28-005 recompetes NIAID's Immune Tolerance Network as a single UM1 cooperative agreement: $27M committed in FY2028, budgets capped at $23M a year in direct costs, a mandatory 7-year project period, one application per institution, and a January 29, 2027 deadline. The winner inherits roughly 20 ongoing trials and about 200 sub-agreements.
Read articleNIAID's RFA-AI-28-024 funds preclinical malaria vaccines, from AI-guided design to cGMP lots, through a phased R61/R33. It allows one application per institution, bars foreign subawards, and excludes GLP tox.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read article